DeepMed Research

Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin

Not Applicable

Completed

Conditions: Laryngopharyngeal Reflux

Interventions: Device: UESAD

First Posted Date: 2015-09-17

Last Posted Date: 2020-02-26

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT02552966

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

Phase 4

Completed

Conditions: Healthy

Interventions: Procedure: Intervention 1
Behavioral: Washout Period
Procedure: Intervention 2

First Posted Date: 2015-09-15

Last Posted Date: 2022-05-16

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT02550093

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

PAI-1 Expression in Non-scarring Hair Loss

Terminated

Conditions: Telogen Effluvium
Alopecia Areata
Androgenetic Alopecia

First Posted Date: 2015-09-14

Last Posted Date: 2022-06-09

Lead Sponsor: Northwestern University

Target Recruit Count: 10

Registration Number: NCT02548689

Locations: 🇺🇸
Northwestern University Department of Dermatology, Chicago, Illinois, United States

Low InTensity Exercise Intervention in PAD

Not Applicable

Completed

Conditions: Peripheral Artery Disease

Interventions: Behavioral: Exercise
Other: Attention control

First Posted Date: 2015-09-02

Last Posted Date: 2021-11-16

Lead Sponsor: Northwestern University

Target Recruit Count: 305

Registration Number: NCT02538900

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Ochsner Baptist, Tulane University, New Orleans, Louisiana, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 1 locations

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Stage IV Breast Cancer

Interventions: Biological: Anti-B7H1 Monoclonal Antibody MEDI4736
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Tremelimumab

First Posted Date: 2015-09-01

Last Posted Date: 2022-05-17

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT02536794

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States

Assessment of Patient Positioning

Completed

Conditions: Neuropraxia

First Posted Date: 2015-08-26

Last Posted Date: 2021-04-06

Lead Sponsor: Northwestern University

Target Recruit Count: 40

Registration Number: NCT02532582

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

Not Applicable

Conditions: Acute Megakaryoblastic Leukemia
Myelofibrosis
Primary Myelofibrosis

Interventions: Drug: Alisertib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-08-21

Last Posted Date: 2021-05-26

Lead Sponsor: Northwestern University

Target Recruit Count: 26

Registration Number: NCT02530619

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1

Terminated

Conditions: Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2015-08-21

Last Posted Date: 2023-11-18

Lead Sponsor: Northwestern University

Target Recruit Count: 4

Registration Number: NCT02530502

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission

Phase 2

Terminated

Conditions: Stage IV Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pidilizumab

First Posted Date: 2015-08-20

Last Posted Date: 2018-03-19

Lead Sponsor: Northwestern University

Target Recruit Count: 4

Registration Number: NCT02530125

Locations: 🇺🇸
Georgia Regents University Medical Center, Augusta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

Intra-articular Morphine and Clonidine Injections for Pain Management in Hip Arthroscopy

Phase 4

Completed

Conditions: Femoracetabular Impingement
Pain, Postoperative

Interventions: Drug: Morphine with clonidine
Other: Normal saline

First Posted Date: 2015-08-20

Last Posted Date: 2019-09-23

Lead Sponsor: Northwestern University

Target Recruit Count: 70

Registration Number: NCT02530151

Locations: 🇺🇸
Joshua Barett, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy